Posted by Michael Wonder on 15 Jul 2025
Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty, the first and only interchangeable rapid acting insulin aspart in the US
15 July 2025 - Biocon Biologics today announced that the US FDA has approved Kirsty (insulin aspart-xjhz), 100 units/mL as the first and only interchangeable biosimilar to NovoLog (insulin aspart).
Kirsty is a rapid-acting human insulin analog indicated to improve glycemic control in adults and paediatric patients with diabetes mellitus.
Kirsty will be available as a single-patient-use pre-filled pen for subcutaneous use and a multiple-dose vial for subcutaneous and intravenous use.
